<DOC>
	<DOCNO>NCT00546676</DOCNO>
	<brief_summary>To determine clinical effectiveness telithromycin treatment either CAP AECB large population ambulatory adult patient community-based setting .</brief_summary>
	<brief_title>Ketek CAP / AECB Ambulatory Adult Patients</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Male female subject great equal 18 year fulfill clinical diagnostic criterion outpatient treatment one two follow community acquire respiratory tract infection ( CARTIs ) : CAP : new pulmonary infiltrate confirm chest Xray least 3 follow sign symptoms infection : fever great equal 38C , cough , chest pain , sputum production , rale , dyspnea , malaise and/or headache ; OR ECB : documented medical history chronic bronchitis subject age 40 present FEV1 &lt; 80 % predict value last 36 month least 2 follow clinical symptom : increase sputum purulence , increase dyspnea and/or increase sputum production . Subjects confirm cardiogenic syncope , ventricular tachyarrythmia Torsades de Pointes take medicinal product QT prolong potential , macrolide quinolone antibiotic , nonantibiotic suspect prolong QT interval ; Pregnancy lactation ; Hypersensitivity macrolides ; Concomitant treatment terfenadine , ergot alkaloid derivative , astemizole pimozide ; Myasthenia gravis ; Antibiotic treatment 30 day prior study entry ; Treatment investigational product 30 day prior study entry and/or previous participation study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>